NASDAQ:PMVP PMV Pharmaceuticals (PMVP) Stock Price, News & Analysis $1.21 +0.11 (+10.00%) Closing price 07/3/2025 03:58 PM EasternExtended Trading$1.21 0.00 (0.00%) As of 07/3/2025 04:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About PMV Pharmaceuticals Stock (NASDAQ:PMVP) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get PMV Pharmaceuticals alerts:Sign Up Key Stats Today's Range$1.06▼$1.1950-Day Range$0.84▼$1.2152-Week Range$0.81▼$1.82Volume582,828 shsAverage Volume197,978 shsMarket Capitalization$62.86 millionP/E RatioN/ADividend YieldN/APrice Target$5.50Consensus RatingBuy Company Overview PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey. Read More PMV Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks62nd Percentile Overall ScorePMVP MarketRank™: PMV Pharmaceuticals scored higher than 62% of companies evaluated by MarketBeat, and ranked 1819th out of 2,814 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingPMV Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoveragePMV Pharmaceuticals has received no research coverage in the past 90 days.Read more about PMV Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for PMV Pharmaceuticals are expected to decrease in the coming year, from ($1.06) to ($1.55) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of PMV Pharmaceuticals is -1.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of PMV Pharmaceuticals is -1.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPMV Pharmaceuticals has a P/B Ratio of 0.36. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about PMV Pharmaceuticals' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.99% of the float of PMV Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverPMV Pharmaceuticals has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in PMV Pharmaceuticals has recently increased by 1.69%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPMV Pharmaceuticals does not currently pay a dividend.Dividend GrowthPMV Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.99% of the float of PMV Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverPMV Pharmaceuticals has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in PMV Pharmaceuticals has recently increased by 1.69%, indicating that investor sentiment is decreasing. News and Social Media2.5 / 5News Sentiment0.41 News SentimentPMV Pharmaceuticals has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for PMV Pharmaceuticals this week, compared to 1 article on an average week.Search Interest1 people have searched for PMVP on MarketBeat in the last 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, PMV Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $121,505.00 in company stock.Percentage Held by InsidersOnly 7.57% of the stock of PMV Pharmaceuticals is held by insiders.Percentage Held by Institutions90.20% of the stock of PMV Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about PMV Pharmaceuticals' insider trading history. Receive PMVP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PMV Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address PMVP Stock News HeadlinesRobert Ticktin Sells 23,151 Shares of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) StockJuly 4 at 8:31 AM | insidertrades.comPmv Pharmaceuticals Inc (PMVP) - Investing.comJuly 3 at 7:11 PM | investing.comElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it takes for the entire thing to burn right up. It’s a NEW internet service poised to disrupt the entire $3.2 trillion telecom industry. But you may only have this chance if you act before December 31st, 2025.July 4 at 2:00 AM | Banyan Hill Publishing (Ad)PMV Pharmaceuticals to Participate at Upcoming Investor ConferencesMay 23, 2025 | globenewswire.comWe're Keeping An Eye On PMV Pharmaceuticals' (NASDAQ:PMVP) Cash Burn RateMay 18, 2025 | finance.yahoo.comPMV Pharmaceuticals, Inc.: PMV Pharmaceuticals Reports First Quarter 2025 Financial Results and Corporate HighlightsMay 9, 2025 | finanznachrichten.dePMV Pharmaceuticals Reports First Quarter 2025 Financial Results and Corporate HighlightsMay 9, 2025 | finance.yahoo.comPMV Pharmaceuticals reports FY24 EPS ($1.14), consensus ($1.02)March 3, 2025 | markets.businessinsider.comSee More Headlines PMVP Stock Analysis - Frequently Asked Questions How have PMVP shares performed this year? PMV Pharmaceuticals' stock was trading at $1.51 at the beginning of the year. Since then, PMVP shares have decreased by 19.9% and is now trading at $1.21. How were PMV Pharmaceuticals' earnings last quarter? PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) issued its quarterly earnings data on Friday, May, 9th. The company reported ($0.34) earnings per share for the quarter, beating analysts' consensus estimates of ($0.37) by $0.03. When did PMV Pharmaceuticals IPO? PMV Pharmaceuticals (PMVP) raised $126 million in an initial public offering (IPO) on Friday, September 25th 2020. The company issued 7,400,000 shares at $16.00-$18.00 per share. Goldman Sachs, BofA Securities, Cowen and Evercore ISI acted as the underwriters for the IPO. How do I buy shares of PMV Pharmaceuticals? Shares of PMVP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of PMV Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that PMV Pharmaceuticals investors own include Avino Silver & Gold Mines (ASM), NIO (NIO), Meta Platforms (META), Plug Power (PLUG), Aptose Biosciences (APTO), Clean Energy Fuels (CLNE) and Intel (INTC). Company Calendar Last Earnings5/09/2025Today7/04/2025Next Earnings (Estimated)8/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PMVP CIK1699382 Webwww.pmvpharma.com Phone609-642-6670FaxN/AEmployees50Year FoundedN/APrice Target and Rating Average Stock Price Target$5.50 High Stock Price Target$6.00 Low Stock Price Target$5.00 Potential Upside/Downside+354.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($1.18) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$58.71 million Net MarginsN/A Pretax MarginN/A Return on Equity-32.54% Return on Assets-29.59% Debt Debt-to-Equity RatioN/A Current Ratio16.75 Quick Ratio16.75 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.40 per share Price / Book0.36Miscellaneous Outstanding Shares51,950,000Free Float48,020,000Market Cap$62.86 million OptionableOptionable Beta1.49 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NASDAQ:PMVP) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredGold: Now legal tender in many statesThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | SponsoredRevealed: NEW A.I. revolution (nobody is talking about)Nvidia's CEO says this is: "The next wave of A.I." We're at the cusp of a new "A.I. Upgrade" that is set to...Behind the Markets | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PMV Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PMV Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.